It is a prime concern of Evotec that all relevant target groups receive the same information at the same time. This implies communicating in both English and German.

Please find below the most recent corporate news, ad hoc releases and other announcements of our Company.

 

2018

Ferring and Evotec form strategic research alliance in reproductive medicine and women’s health
Nerina Coppini, 17 October 2018

Ferring accesses Evotec's integrated small molecule discovery and development platform to progress new molecules from concept to potential drug candidates Evotec is eligible for undisclosed research funding and milestones 

Evotec and Celgene expand IPSC collaboration to include additional cell lines
Nerina Coppini, 11 October 2018

$ 6 M payment to access additional cell lines

Evotec signs agreement with Sanofi to advance early stage academic research into novel therapeutic candidates
Nerina Coppini, 4 October 2018

The creation of LAB031 is designed to translate academic research into drug discovery candidates Evotec aims to generate multiple lead candidates for Sanofi over three years across multiple therapeutic categories

 

Other announcements

Merger

The following annoucement has been published in the German Federal Gazette in accordance with the German Conversion Act (Umwandlungsgesetz) in 2013. Pursuant to the German Conversion Act, certain transaction intended by Evotec AG, e.g. up-stream mergers, have to be announced in the Federal Gazette (Bundesanzeiger).

Contact us

Gabriele Hansen

VP, Corporate Communications & Investor Relations

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Katja Werner

Investor Relations Associate

T +49 40 560 81 210 F +49 40 560 81 333 vCard